Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 75-82

  Watanabe, Osamu ^a,b   Kinoshita, J ^a   Shimizu, T ^a   Imamura, H ^a   Hirano, A ^a   Okabe, T ^a   Aiba, M ^a   Ogawa, K ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Breast cancer; CD44; Prognostic factor; VEGF C

Indexed keywords

CD44V ANTIGEN; CD44V7V8 ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME;

ANTIGENS, CD44; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MUTATION; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; VARIATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 18544364014     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Choi S.H., Barsky S.H., Chang H.R.: Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J. 9(3): 153-162, 2003.
2. Stamenkovic I., Amito M., Pesando J.M., Seed B.: A lymphocyte molecule implicated in lymph node homing is a number of cartilage link protein family. Cell 56: 1057-1062, 1989.
3. Günthert U., Hofmann M., Rudy W., Rober S., Zöller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P.: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
4. Thomas L., Byers H.R., Vink J., Stamenkovic I.: CD44 regulates tumor cell migration on hyaluronate-coated substrate. J. Cell Biol. 118: 971-977, 1992.
5. Ruiz P., Schwarzler C., Günthert U.: CD44 isoforms during differentiation and development. Bioessays 17: 17-24, 1995.
6. Tokue Y., Matsumura Y., Katsumata N., Watanabe T., Tarin D., Kakizoe T.: CD44 variant isoform expression and breast cancer prognosis. Jpn. J. Cancer Res. 89: 283-290, 1998.
7. Berner H.S., Suo Z., Risberg B., Villman K., Karlsson M.G., Nesland J.M.: Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42(6): 546-554, 2003.
8. Kinoshita J., Haga S., Shimizu T., Imamura H., Watanabe O., Kajiwara T.: The expression of variant exon CD44 v7-v8 antigen in relation to lymphatic metastasis of human breast cancer. Breast Cancer Res. Treat. 53: 177-183, 1999.
9. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E., Weich H.A., Christ B., Alitalo K., Wilting J.: VEGF and VEGF-C; specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188: 96-109, 1997.
10. Kurebayashi J., Otsuki T., Kunisue H., Mikami Y., Tanaka K., Yamamoto S., Sonoo H.: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. 90: 977-981, 1999.
11. Nakamura Y., Yasuoka H., Tsujimoto M., Yang Q., Tsukiyama A., Imabun S., Nakahara M., Nakao K., Nakamura M., Mori I., Kakudo K.: Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod. Pathol. 16(4): 309-314, 2003.
12. Ishikawa M., Kitayama J., Kazama S., Nagawa H.: Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn. J. Clin. Oncol. 33(1): 21-27, 2003.
13. Ohno M., Nakamura T., Kunimoto Y., Nishimura K., Chung-Kang C., Kuroda Y.: Lymphagenesis correlates with expression of vascular endothelial growth factor-C in colorectal cancer. Oncol. Rep. 10(4): 939-943, 2003.
14. Ohta Y., Nozawa H., Tanaka Y., Oda M., Watanabe Y.: Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 119:804-813, 2000.
15. Tsurusaki T., Kanda S., Sakai H., Kanetake H., Saito Y., Alitalo K., Koji T.: Vascular endothelial growth factor-C expression pression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J. Cancer 80: 309-313, 1999.
16. Neuchrist C., Erovic B.M., Handisurya A., Fischer M.B., Steiner G.E., Hollemann D., Gedlicka C., Saaristo A., Burian M.: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25: 464-474, 2003.
17. Nakashima T., Kondoh S., Kitoh H., Ozawa H., Okita S., Harada T., Shiraishi K., Ryozawa S., Okita K.: Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int. J. Mol. Med. 11(1): 33-39, 2003.
18. Ueda M., Terai Y., Yamashita Y., Kumagai K., Ueki K., Yamaguchi H., Akise D., Hung Y., Ueki M.: Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int. J. Cancer 98: 335-343, 2002.
19. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Calaffey K., Detmar M.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7(2): 186-191, 2001.
20. Mattila M.M., Ruohola J.K., Karpanen T., Jackson D.G., Alitalo K., Harkonen P.L.: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 98(6): 946-951, 2002.
21. Dall P., Heider K.H., Hekele A., von Minckwitz G., Kaufmann M., Ponta H., Herrlich P.: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res. 54: 3337-3341, 1994.
22. Saegusa M., Hashimura M., Machida D., Okayasu I.: Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumors. J. Pathol. 187: 173-183, 1999.
23. Friedrichs K., Franke F., Lisboa B.-W., Kungler G., Terpe H.-J., Holzer F., Maass H., Günthert U.: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 55: 5424-5433, 1995.
24. Foekens J.A., Dall P., Klijn J.G., Skroch-Angel P., Claassen C.J., Look M.P., Ponta H., Van Putten W.L., Herrlich P., Henzen-Logmans S.C.: Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 84: 209-215, 1999.
25. Seiter S., Arch R., Reber S., Komitowski D., Hofmann M., Ponta H., Herrlich P., Matzku S., Zoller M.: Prevention of tumor metastasis formation by anti-variant CD44. J. Exp. Med. 177: 443-455, 1993.
26. Özel E., Canda T., Kurtodlu B.: The role of angiogenesis, laminin and CD44 expression in metastatic behavior of early-stage low-grade invasive breast carcinomas. Cancer Lett. 121: 119-123, 1997.
27. Jansen R.H., Joosten-Achjanie S.R., Arenas J.W., Volovics A., Hupperets P.S., Schouten H.C., Hillen H.F.: CD44v6 is not a prognostic: factor in primary breast cancer. Ann. Oncol. 9: 109-111, 1998.
28. Schumacher U., Hoeny H.-P., Horst H.-A., Herrlich P., Kaiserling E.: A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Euro J. Surg. Oncol. 22: 259-261, 1996.
29. Guriec N., Gairard B., Marcellin L., Wilk A., Calderoli H., Renaud R., Bergerat J.P., Oberling F.: CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas. Breast Cancer Res. Treat. 44: 261-268, 1997.
30. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K.: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinase. EMBO J. 15: 290-298, 1996.
31. Williams C.S., Leek R.D., Robson A.M., Banerji S., Prevo R., Harris A.L., Jackson D.G.: Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J. Pathol. 200(2): 195-206, 2003.
32. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., Jain R.K.: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1811-1812, 2002.
33. Ohta Y., Nozawa H., Tanaka Y., Oda M., Watanabe Y.: Increased vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 119: 804-813, 2000.
34. Kinoshita J., Kitamura K., Kabashima A., Saeki H., Tanaka S., Sugimachi K.: Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res. Treat. 66: 159-164, 2001.
35. Tempfer C., Lösch A., Häusler G.; Heinzl H., Kölbl H., Breitennecker G., Kainz Ch.: Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-v8 in human breast cancer. Eur. J. Cancer 32A: 2023-2025, 1996.